Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Operating expenses
Research and development	$ 5,316	$ 3,988
General and administrative	2,854	2,643
Change in fair value of contingent consideration	299	(858)
Total operating expenses	8,469	5,773
Operating loss	(8,469)	(5,773)
Other income
Change in fair value of warrants liabilities		27
Interest income	113	22
Total other income	113	49
Net loss	(8,356)	(5,724)
Other comprehensive income (loss)
Foreign currency translation adjustment	16	(2)
Total comprehensive loss	$ (8,340)	$ (5,726)
Net loss per common share basic	$ (0.88)	$ (1.07)
Net loss per common share diluted	$ (0.88)	$ (1.07)
Weighted-average common shares outstanding used to calculate basic net loss per common share	9,447,350	5,334,712
Weighted-average common shares outstanding used to calculate diluted net loss per common share	9,447,350	5,334,712